Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Munsat, T. L.
Right arrow Articles by Hiatt, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Munsat, T. L.
Right arrow Articles by Hiatt, R.
NEUROLOGY 1981;31:1054
© 1981 American Academy of Neurology

Amantadine and guanidine are ineffective in ALS

Theodore L. Munsat, M.D., Catherine Schmidt Easterday, M.S., RPT, Steven Levy, M.D., Sheldon M. Wolff, M.D. and Robert Hiatt, D. Pharm.

Department of Neurology, School of Medicine, University of California, San Francisco, CA.

Address correspondence and reprint requests to Dr. Munsat, Tufts-New England Medical Center, Department of Neurology, 171 Harrison Avenue, Boston, MA 02111.

Amantadine and guanidine were evaluated in two groups of 10 amyotrophic lateral sclerosis patients each. In a double-blind, crossover design lasting 1 year, neither drug showed therapeutic benefit as compared to placebo.




This article has been cited by other articles:


Home page
Arch NeurolHome page
H. Mitsumoto, M. R. Hanson, and D. A. Chad
Amyotrophic Lateral Sclerosis: Recent Advances in Pathogenesis and Therapeutic Trials
Arch Neurol, February 1, 1988; 45(2): 189 - 202.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1981 by AAN Enterprises, Inc.